Cargando…

KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer

INTRODUCTION: Circulating tumor cells (CTCs) could represent a non-invasive source of cancer cells used for longitudinal monitoring of the tumoral mutation status throughout the course of the disease. The aims of the present study were to investigate the detection of KRAS mutations in CTCs from pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalikaki, Aristea, Politaki, Helen, Souglakos, John, Apostolaki, Stella, Papadimitraki, Elisavet, Georgoulia, Nefeli, Tzardi, Maria, Mavroudis, Dimitris, Georgoulias, Vassilis, Voutsina, Alexandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138105/ https://www.ncbi.nlm.nih.gov/pubmed/25137394 http://dx.doi.org/10.1371/journal.pone.0104902

Ejemplares similares

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2(nd) Line Cetuximab-Based Therapy of Colorectal Cancer Patients
por: Saridaki, Zacharenia, et al.
Publicado: (2011)

BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients’ Outcome
por: Saridaki, Zacharenia, et al.
Publicado: (2013)

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer()
por: Matikas, Alexios, et al.
Publicado: (2017)

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2011)

TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC)
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Papadaki, Maria A., et al.
Publicado: (2021)

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer
por: Polioudaki, Hara, et al.
Publicado: (2015)

Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib
por: Messaritakis, Ippokratis, et al.
Publicado: (2018)

PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
por: Tzanikou, Eleni, et al.
Publicado: (2019)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status
por: Souglakos, John, et al.
Publicado: (2006)

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2022)

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
por: Saridaki, Z, et al.
Publicado: (2012)

Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
por: Koulouridi, Asimina, et al.
Publicado: (2022)

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse
por: Saloustros, Emmanouil, et al.
Publicado: (2011)

Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR
por: Strati, Areti, et al.
Publicado: (2011)

Role of circulating free DNA in colorectal cancer
por: Matikas, Alexios, et al.
Publicado: (2016)

A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update
por: Thomopoulou, K., et al.
Publicado: (2019)

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2019)

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer
por: Messaritakis, Ippokratis, et al.
Publicado: (2018)

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2014)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
por: Matikas, Alexios, et al.
Publicado: (2015)

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer
por: Androulakis, N, et al.
Publicado: (2012)

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
por: Papadaki, Maria A, et al.
Publicado: (2014)

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2008)

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2015)

Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide
por: Karachaliou, Niki, et al.
Publicado: (2013)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
por: Emmanouilides, Christos, et al.
Publicado: (2007)

Evaluation of the Role of Circulating Tumor Cells and Microsatellite Instability Status in Predicting Outcome of Advanced CRC Patients
por: Messaritakis, Ippokratis, et al.
Publicado: (2020)

Favorable Clinical Course of Patients Experiencing Bevacizumab-Induced Proteinuria
por: Saloustros, Emmanouil, et al.
Publicado: (2010)

Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy
por: Spiliotaki, Maria, et al.
Publicado: (2014)

Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment
por: Koulouridi, Asimina, et al.
Publicado: (2021)

Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2009)

Expression of insulin‐like growth factor‐1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes
por: Spiliotaki, Maria, et al.
Publicado: (2017)

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer
por: Xenidis, N, et al.
Publicado: (2013)

A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients
por: Vetsika, Eleni-Kyriaki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ll13e0dhg330hqn8e4v49sbmta